David Risinger
Stock Analyst at Leerink Partners
(4.49)
# 222
Out of 4,842 analysts
170
Total ratings
65.17%
Success rate
13.59%
Average return
Main Sectors:
Stocks Rated by David Risinger
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| JNJ Johnson & Johnson | Downgrades: Market Perform | $169 → $153 | $152.43 | +0.37% | 4 | May 13, 2025 | |
| VRTX Vertex Pharmaceuticals | Downgrades: Market Perform | $550 → $503 | $445.10 | +13.01% | 4 | May 6, 2025 | |
| REGN Regeneron Pharmaceuticals | Upgrades: Outperform | $762 → $834 | $591.85 | +40.91% | 8 | Feb 5, 2025 | |
| ABBV AbbVie | Upgrades: Outperform | $206 | $183.09 | +12.51% | 7 | Nov 22, 2024 | |
| BMY Bristol-Myers Squibb Company | Upgrades: Outperform | $55 → $73 | $46.97 | +55.42% | 4 | Nov 12, 2024 | |
| TECX Tectonic Therapeutic | Maintains: Outperform | $49 → $69 | $21.56 | +220.04% | 2 | Nov 11, 2024 | |
| TENX Tenax Therapeutics | Initiates: Outperform | $16 | $6.07 | +163.59% | 1 | Oct 24, 2024 | |
| ORKA Oruka Therapeutics | Initiates: Outperform | $44 | $11.47 | +283.61% | 2 | Sep 17, 2024 | |
| PCVX Vaxcyte | Maintains: Outperform | $106 → $153 | $31.38 | +387.57% | 2 | Sep 3, 2024 | |
| TBPH Theravance Biopharma | Downgrades: Market Perform | $15 → $10 | $9.14 | +9.41% | 3 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $28 → $2 | $1.85 | +8.40% | 2 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $47 | $20.90 | +124.88% | 1 | Apr 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $267 → $318 | $278.40 | +14.22% | 4 | Oct 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $6 → $11 | $12.95 | -15.06% | 2 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $410 → $458 | $719.39 | -36.33% | 16 | May 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $42 | $54.43 | -22.84% | 3 | Mar 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $81 → $91 | $108.44 | -16.08% | 3 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $49 → $48 | $23.18 | +107.08% | 14 | Feb 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $8 → $10 | $10.62 | -5.84% | 4 | Dec 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $7 → $10 | $29.54 | -66.15% | 2 | Jun 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $35 → $37 | $9.15 | +304.37% | 2 | Feb 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $162 → $176 | $107.01 | +64.47% | 3 | Apr 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $18 → $16 | $8.59 | +86.26% | 1 | Mar 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $53 → $45 | $27.10 | +66.05% | 17 | Mar 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $22 → $35 | $4.55 | +669.23% | 4 | Feb 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $31 → $41 | $13.40 | +205.97% | 5 | Nov 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $167 → $174 | $165.40 | +5.20% | 9 | Nov 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $51 | $32.63 | +56.30% | 1 | Jul 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $13 → $8 | $18.15 | -55.92% | 19 | Apr 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $97 → $89 | $76.17 | +16.84% | 8 | Apr 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $5 → $3 | $7.21 | -58.39% | 4 | Apr 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $20 → $16 | $29.90 | -46.49% | 9 | Apr 2, 2020 |
Johnson & Johnson
May 13, 2025
Downgrades: Market Perform
Price Target: $169 → $153
Current: $152.43
Upside: +0.37%
Vertex Pharmaceuticals
May 6, 2025
Downgrades: Market Perform
Price Target: $550 → $503
Current: $445.10
Upside: +13.01%
Regeneron Pharmaceuticals
Feb 5, 2025
Upgrades: Outperform
Price Target: $762 → $834
Current: $591.85
Upside: +40.91%
AbbVie
Nov 22, 2024
Upgrades: Outperform
Price Target: $206
Current: $183.09
Upside: +12.51%
Bristol-Myers Squibb Company
Nov 12, 2024
Upgrades: Outperform
Price Target: $55 → $73
Current: $46.97
Upside: +55.42%
Tectonic Therapeutic
Nov 11, 2024
Maintains: Outperform
Price Target: $49 → $69
Current: $21.56
Upside: +220.04%
Tenax Therapeutics
Oct 24, 2024
Initiates: Outperform
Price Target: $16
Current: $6.07
Upside: +163.59%
Oruka Therapeutics
Sep 17, 2024
Initiates: Outperform
Price Target: $44
Current: $11.47
Upside: +283.61%
Vaxcyte
Sep 3, 2024
Maintains: Outperform
Price Target: $106 → $153
Current: $31.38
Upside: +387.57%
Theravance Biopharma
Aug 6, 2024
Downgrades: Market Perform
Price Target: $15 → $10
Current: $9.14
Upside: +9.41%
Jul 9, 2024
Downgrades: Market Perform
Price Target: $28 → $2
Current: $1.85
Upside: +8.40%
Apr 16, 2024
Initiates: Outperform
Price Target: $47
Current: $20.90
Upside: +124.88%
Oct 11, 2023
Upgrades: Outperform
Price Target: $267 → $318
Current: $278.40
Upside: +14.22%
Aug 15, 2023
Maintains: Outperform
Price Target: $6 → $11
Current: $12.95
Upside: -15.06%
May 1, 2023
Maintains: Outperform
Price Target: $410 → $458
Current: $719.39
Upside: -36.33%
Mar 16, 2023
Downgrades: Market Perform
Price Target: $42
Current: $54.43
Upside: -22.84%
Feb 3, 2023
Maintains: Market Perform
Price Target: $81 → $91
Current: $108.44
Upside: -16.08%
Feb 1, 2023
Maintains: Market Perform
Price Target: $49 → $48
Current: $23.18
Upside: +107.08%
Dec 19, 2022
Maintains: Outperform
Price Target: $8 → $10
Current: $10.62
Upside: -5.84%
Jun 24, 2022
Maintains: Market Perform
Price Target: $7 → $10
Current: $29.54
Upside: -66.15%
Feb 22, 2022
Maintains: Equal-Weight
Price Target: $35 → $37
Current: $9.15
Upside: +304.37%
Apr 1, 2021
Maintains: Equal-Weight
Price Target: $162 → $176
Current: $107.01
Upside: +64.47%
Mar 10, 2021
Maintains: Equal-Weight
Price Target: $18 → $16
Current: $8.59
Upside: +86.26%
Mar 5, 2021
Maintains: Equal-Weight
Price Target: $53 → $45
Current: $27.10
Upside: +66.05%
Feb 26, 2021
Maintains: Equal-Weight
Price Target: $22 → $35
Current: $4.55
Upside: +669.23%
Nov 24, 2020
Maintains: Overweight
Price Target: $31 → $41
Current: $13.40
Upside: +205.97%
Nov 13, 2020
Maintains: Equal-Weight
Price Target: $167 → $174
Current: $165.40
Upside: +5.20%
Jul 13, 2020
Initiates: Equal-Weight
Price Target: $51
Current: $32.63
Upside: +56.30%
Apr 2, 2020
Maintains: Underweight
Price Target: $13 → $8
Current: $18.15
Upside: -55.92%
Apr 2, 2020
Maintains: Overweight
Price Target: $97 → $89
Current: $76.17
Upside: +16.84%
Apr 2, 2020
Maintains: Equal-Weight
Price Target: $5 → $3
Current: $7.21
Upside: -58.39%
Apr 2, 2020
Maintains: Equal-Weight
Price Target: $20 → $16
Current: $29.90
Upside: -46.49%